JYMLEEP Trademark

Trademark Overview


On Tuesday, December 19, 2023, a trademark application was filed for JYMLEEP with the United States Patent and Trademark Office. The USPTO has given the JYMLEEP trademark a serial number of 98322370. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Friday, November 8, 2024. This trademark is owned by Deciphera Pharmaceuticals, LLC. The JYMLEEP trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for treating tenosynovial giant cell tumor (TGCT), giant cell tumor of the tendon sheath (GCT-TS), and pigmented villonodular synovitis (PVNS); Pharmaceutical and biological preparations for use in orthopedics, rheumatology, oncology, neurology, immunology, and hematology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions affecting the musculoskeletal system, central nervous system, immune system, and blood; Pharmaceutical and biological preparations for treating tumors, sarcomas, tenosynovial giant cell tumors, graft versus host disease (GVHD), Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS); Therapeutic agents, namely, kinase inhibitors
jymleep

General Information


Serial Number98322370
Word MarkJYMLEEP
Filing DateTuesday, December 19, 2023
Status653 - SUSPENSION LETTER - MAILED
Status DateFriday, November 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for treating tenosynovial giant cell tumor (TGCT), giant cell tumor of the tendon sheath (GCT-TS), and pigmented villonodular synovitis (PVNS); Pharmaceutical and biological preparations for use in orthopedics, rheumatology, oncology, neurology, immunology, and hematology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions affecting the musculoskeletal system, central nervous system, immune system, and blood; Pharmaceutical and biological preparations for treating tumors, sarcomas, tenosynovial giant cell tumors, graft versus host disease (GVHD), Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS); Therapeutic agents, namely, kinase inhibitors

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 19, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDeciphera Pharmaceuticals, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressWaltham, MA 02451

Trademark Events


Event DateEvent Description
Tuesday, December 19, 2023NEW APPLICATION ENTERED
Thursday, March 28, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 18, 2024ASSIGNED TO EXAMINER
Monday, July 22, 2024NON-FINAL ACTION E-MAILED
Monday, July 22, 2024NON-FINAL ACTION WRITTEN
Monday, July 22, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 8, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, November 8, 2024SUSPENSION LETTER WRITTEN
Friday, November 8, 2024LETTER OF SUSPENSION E-MAILED